Results 111 to 120 of about 2,015,361 (384)

Identification of myoferlin as a mitochondria-associated membranes component required for calcium signaling in PDAC cell lines

open access: yesCell Communication and Signaling
Background Pancreatic ductal adenocarcinoma is an aggressive cancer type with one of the lowest survival rates due to late diagnosis and the absence of effective treatments.
Sandy Anania   +8 more
doaj   +1 more source

E-cadherin is required for metastasis in multiple models of breast cancer

open access: yesNature, 2019
Metastasis is the major driver of death in patients with cancer. Invasion of surrounding tissues and metastasis have been proposed to initiate following loss of the intercellular adhesion protein, E-cadherin1,2, on the basis of inverse correlations ...
Veena Padmanaban   +6 more
semanticscholar   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Ferlin Overview: From Membrane to Cancer Biology

open access: yesCells, 2019
In mammal myocytes, endothelial cells and inner ear cells, ferlins are proteins involved in membrane processes such as fusion, recycling, endo- and exocytosis. They harbour several C2 domains allowing their interaction with phospholipids.
Olivier Peulen   +5 more
doaj   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

open access: yesMolecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang   +8 more
wiley   +1 more source

Narciclasine as a potential therapeutic agent to overcome EGFR-TKI resistance in non-small cell lung cancer

open access: yesJournal of Translational Medicine
Background Non-small cell lung cancer (NSCLC) is associated with abnormal activation of the epidermal growth factor receptor (EGFR) due to overexpression or mutations.
Jee Young Sung   +11 more
doaj   +1 more source

Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine releaseResearch in context

open access: yesEBioMedicine, 2019
Background: Treatment multiple tumors by immune therapy can be achieved by mobilizing both innate and adaptive immunity. The programmed death ligand 1 (PD-L1; or CD274, B7-H1) is a critical “don't find me” signal to the adaptive immune system.
Shu Lian   +9 more
doaj   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

ORGAN SPECIFIC VASCULAR RESPONSE TO FIBROSIS AFFECTS BREAST CANCER METASTATIC ORGANOTROPISM [PDF]

open access: yes, 2016
The solid tumor microenvironment, pre-metastatic niche, and fibrotic environment are known to have significant biochemical and biomechanical similarities to the fibrotic environment. All have significantly increased levels of factors such as TGFβ, HIF1α,
Fletcher, Eliot S, Fletcher, Eliot S
core   +1 more source

Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer [PDF]

open access: hybrid, 2019
Qinglei Gao   +23 more
openalex   +1 more source

Home - About - Disclaimer - Privacy